Zhejiang Huahai Pharmaceutical Gestione

Gestione criteri di controllo 1/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Bao Hua Chen

Amministratore delegato

CN¥2.2m

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	no data
Proprietà del CEO	25.5%
Durata media del management	Nessun dato
Durata media del Consiglio di amministrazione	Nessun dato

Aggiornamenti recenti sulla gestione

Recent updates

Investors Holding Back On Zhejiang Huahai Pharmaceutical Co., Ltd. (SHSE:600521)

Oct 22

Here's Why Zhejiang Huahai Pharmaceutical (SHSE:600521) Has A Meaningful Debt Burden

Sep 25

Zhejiang Huahai Pharmaceutical Co., Ltd.'s (SHSE:600521) Intrinsic Value Is Potentially 89% Above Its Share Price

Jun 20

Zhejiang Huahai Pharmaceutical (SHSE:600521) Takes On Some Risk With Its Use Of Debt

May 28

There May Be Some Bright Spots In Zhejiang Huahai Pharmaceutical's (SHSE:600521) Earnings

May 06

Investors Don't See Light At End Of Zhejiang Huahai Pharmaceutical Co., Ltd.'s (SHSE:600521) Tunnel

Mar 22

AMMINISTRATORE DELEGATO

Bao Hua Chen (62 yo)

no data

Mandato

CN¥2,180,000

Compensazione

Mr. Bao Hua Chen serves as the President of TCM BU at Shanghai Pharmaceutical (Group) Co., Ltd. Mr. Chen serves as General Manager and Director at Zhejiang Huahai Pharmaceutical Co., Ltd and serves as its...

Zhejiang Huahai Pharmaceutical Gestione

Gestione criteri di controllo 1/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Zhejiang Huahai Pharmaceutical Co., Ltd., Annual General Meeting, May 21, 2024

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.19 (vs CN¥0.11 in 3Q 2023)

Investors Holding Back On Zhejiang Huahai Pharmaceutical Co., Ltd. (SHSE:600521)

Zhejiang Huahai Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 31, 2024

Investor sentiment improves as stock rises 25%

Here's Why Zhejiang Huahai Pharmaceutical (SHSE:600521) Has A Meaningful Debt Burden

Second quarter 2024 earnings released: EPS: CN¥0.33 (vs CN¥0.27 in 2Q 2023)

Consensus EPS estimates increase by 14%

Dividend reduced to CN¥0.20

Zhejiang Huahai Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 31, 2024

Zhejiang Huahai Pharmaceutical Co., Ltd.'s (SHSE:600521) Intrinsic Value Is Potentially 89% Above Its Share Price

Zhejiang Huahai Pharmaceutical (SHSE:600521) Takes On Some Risk With Its Use Of Debt

There May Be Some Bright Spots In Zhejiang Huahai Pharmaceutical's (SHSE:600521) Earnings

Price target increased by 11% to CN¥18.17

Zhejiang Huahai Pharmaceutical Co., Ltd., Annual General Meeting, May 21, 2024

First quarter 2024 earnings released: EPS: CN¥0.19 (vs CN¥0.12 in 1Q 2023)

Full year 2023 earnings released: EPS: CN¥0.57 (vs CN¥0.81 in FY 2022)

Investor sentiment improves as stock rises 18%

Zhejiang Huahai Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024

Investors Don't See Light At End Of Zhejiang Huahai Pharmaceutical Co., Ltd.'s (SHSE:600521) Tunnel

Investor sentiment improves as stock rises 17%

Consensus revenue estimates fall by 10%

Price target decreased by 11% to CN¥17.60

Zhejiang Huahai Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Apr 30, 2024

Zhejiang Huahai Pharmaceutical Co., Ltd. (SHSE:600521) announces an Equity Buyback for CNY 100 million worth of its shares.

Consensus EPS estimates fall by 13%

Third quarter 2023 earnings released: EPS: CN¥0.11 (vs CN¥0.16 in 3Q 2022)

Price target decreased by 10% to CN¥20.63

Second quarter 2023 earnings released: EPS: CN¥0.27 (vs CN¥0.28 in 2Q 2022)

Full year 2022 earnings released: EPS: CN¥0.81 (vs CN¥0.34 in FY 2021)

Consensus EPS estimates increase by 11%

Investor sentiment improved over the past week

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.16 (vs CN¥0.053 in 3Q 2021)

Price target increased to CN¥18.00

Second quarter 2022 earnings released: EPS: CN¥0.28 (vs CN¥0.17 in 2Q 2021)

Zhejiang Huahai Pharmaceutical Co., Ltd. announced that it expects to receive CNY 1.56 billion in funding

Price target increased to CN¥15.50

Investor sentiment improved over the past week

Full year 2021 earnings released: EPS: CN¥0.34 (vs CN¥0.64 in FY 2020)

Price target increased to CN¥15.50

Less than half of directors are independent

Full year 2021 earnings released: EPS: CN¥0.34 (vs CN¥0.64 in FY 2020)

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Price target increased to CN¥15.50

Second quarter 2021 earnings released: EPS CN¥0.17 (vs CN¥0.24 in 2Q 2020)

Zhejiang Huahai Pharmaceutical Co., Ltd. (SHSE:600521) announces an Equity Buyback for CNY 200 million worth of its shares.

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS CN¥0.18 (vs CN¥0.15 in 1Q 2020)

Investor sentiment deteriorated over the past week

Full year 2020 earnings released: EPS CN¥0.64 (vs CN¥0.41 in FY 2019)

New 90-day low: CN¥28.88

Market bids up stock over the past week

Third quarter 2020 earnings released: EPS CN¥0.18

New 90-day low: CN¥31.49

Price target raised to CN¥12.27

Third quarter earnings released

Zhejiang Huahai Pharmaceutical Co., Ltd. to Report Q3, 2020 Results on Oct 20, 2020

Analysts update estimates

New 90-day low: CN¥31.92

First half earnings released

New 90-day high - CN¥44.83

New 90-day high - CN¥41.96

AMMINISTRATORE DELEGATO

Mandato

Compensazione